Niaid VRC - premise - pandemic response repository through microbial and immunologic surveillance and epidemiology
Active Awarded Last action
- Contract number
- 75N91022F00005
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $11,527,609
Award facts
- Opportunity
-
- NIAIDVRC220042 Solicitation number
- Contract value 100% obligated
- $11,527,609.00 Current and potential, with all options
- Completion date 55% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $885,777 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $2,900,715 | |
| Other Administrative Action | $2,344,095 | |
| Exercise an Option | $3,211,802 | |
| Original award | $2,185,220 |
About this award
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH), a civilian agency. The contract was awarded to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc., on March 4, 2022. The contract is for the PREMISE - Pandemic Response Repository through Microbial and Immunologic Surveillance and Epidemiology program, with a ceiling value of $11,527,609.00 and a completion date of July 30, 2030. The contract is a delivery order with a cost-plus-fixed-fee pricing type and does not have a set-aside designation. Leidos Biomedical Research Inc. is a Federally Funded Research and Development Center (FFRDC) contractor for the National Cancer Institute (NCI) and has extensive capabilities in biomedical research and support services for federal agencies, particularly the NIH.
Quick answers
Who was awarded contract 75N91022F00005?
75N91022F00005 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on March 4, 2022.
How much is contract 75N91022F00005 worth?
The government has obligated $11,527,609 on 75N91022F00005.
Which agency awarded contract 75N91022F00005?
National Cancer Institute (National Institutes of Health) awarded 75N91022F00005, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91022F00005 an order under another contract?
Yes. 75N91022F00005 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91022F00005 competed?
The extent of competition for 75N91022F00005 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award